SPL 9.20% 9.5¢ starpharma holdings limited

I believe the CEO is pursuing sale of the DEP cancer drug...

  1. 4,843 Posts.
    lightbulb Created with Sketch. 250
    I believe the CEO is pursuing sale of the DEP cancer drug platform the sale will include all current in house drugs along with a large patent portfolio and listed applications. The sale will create a large cash chest for Starpharma to pursue their existing products and applications, the CEO hinted at this possibility in a recent interview. As far as potential value of moneyterizing the platform I am not sure something approaching $400m I would guess. This is just my opinion and not financial advice.
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
(20min delay)
Last
9.5¢
Change
0.008(9.20%)
Mkt cap ! $39.14M
Open High Low Value Volume
9.0¢ 9.5¢ 8.8¢ $334.2K 3.710M

Buyers (Bids)

No. Vol. Price($)
2 50354 9.4¢
 

Sellers (Offers)

Price($) Vol. No.
9.5¢ 22908 2
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
SPL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.